Thursday, 25 April 2019

Pulmonary Atresia Diagnostics and Treatment Market size and Key Trends in terms of volume and value 2019

Pulmonary atresia is the type of inherited heart defect that a baby is born with. It arises when the pulmonary valve normally located between the right ventricle and the pulmonary artery doesn’t form properly. The valve should have three leaflets which allow the blood to flow forward into the pulmonary artery but prevent it from flowing backward into the right ventricle. In the case of congenital pulmonary atresia patients, the valve either malfunctions or does not form at all. The tissue formed in the place of pulmonary valve does not allow the blood flow into the pulmonary artery. This flaw develops in the first eight weeks of pregnancy and disturbs the flow of blood from the right ventricle to the pulmonary artery leading to the lungs. It can be recognized in a prenatal ultrasound.
The Global Pulmonary Atresia Diagnostics and Treatment Market is expected to register a significant growth during the forecast period (2018–2023).
The most common symptoms are blue or gray-toned skin, troubled breathing, weakness, sleepiness, and others. Factors such as technological advancements, increasing awareness, lifestyle changes are the major driving factors for the growth of the market. However, unspecified regulatory issues, infection risks connected with surgical procedures, and ambiguous reimbursement policies are the factors limiting the market growth. Additionally, restrains for the market include the high cost of the surgical procedure and the risks involved in the procedures are likely to affect the pulmonary atresia diagnostics and treatment market negatively. 
Key Players
Some of the key players in the global pulmonary atresia diagnostics and treatment market are Kyowa Pharma Chemical Co. Ltd, AZAD partners, Abbott Laboratories, Dickinson and Company, Becton, C. R. Bard, Inc., B. Braun Melsungen AG, Medtronic plc., Teleflex Incorporated, JOHNSON & JOHNSON, Cook Group Incorporated, and Boston Scientific Corporation.
Segmentation
The global pulmonary atresia diagnostics and treatment market has been segmented on the basis of type, diagnosis, treatment and end users.
On the basis of treatment, the market has been classified as medication, cardiac catheterization, surgery. The cardiac catheterization is segmented into radiofrequency ablation and balloon valvotomy, balloon atrial septostomy, and stent placement. The surgery is segmented into right ventricular outflow reconstruction, blalock-taussig shunt, bi-directional glenn procedure, fontan procedure, and heart transplant.
On the basis of type, the market has been classified as pulmonary atresia with an intact ventricular septum and pulmonary atresia with ventricular septum defect.
On the basis of diagnosis, the market has been classified as pulse oximetry, electrocardiogram (ECG), echocardiogram (cardiac ultrasound), cardiac MRI and cardiac catheterization.
On the basis of end users, the market has been classified as hospitals, clinics, diagnostic centers, specialty clinics, research institutes, and others.
On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.
The European pulmonary atresia diagnostics and treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The pulmonary atresia diagnostics and treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The pulmonary atresia diagnostics and treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.
Regional Market Summary
The European market is expected to hold the second largest market share. Factors such as a rise in research expenses, advancement of technology, the decline in human health, and the necessity for innovative and effective therapies boost the growth of the market in this region. According to the Centers for Disease Control and Prevention, congenital heart defects are a foremost cause of birth defect associated with infant illness and deaths. The deaths often occur when the infant is less than 28 days old and hence diagnosis of the defect is utmost important.
In the pulmonary atresia diagnostics and treatment market, North America is anticipated to account for the largest market share due to the early adoption of advanced medical technologies, continuous development by companies operating into medical devices manufacturing. According to the Centers for Disease Control and Prevention, about 40,000 births are affected by congenital heart defects in the US every year.
Whereas the market share in Asia-Pacific region is also anticipated to experience growth in the near future due to access to optimal treatment facilities and growing demand for increasing government initiatives, advanced technology, better adoption rate, and rising healthcare expenditure.
The market in the Middle East & Africa is expected to account for the smallest share of the global pulmonary atresia diagnostics and treatment market due to an underdeveloped healthcare sector, the dearth of technical knowledge, and poor medical facilities.
Browse Complete 100 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/pulmonary-atresia-diagnostics-treatment-market-6487


About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Posted by at No comments:

Endovascular Aneurysm Repair Devices Market to show steady growth, 2019

Market Scenario
Global endovascular aneurysm repair devices market is likely to grow significantly over the forecast period. It is estimated that the global endovascular aneurysm repair devices market is expected to record a CAGR ~ 6.4 % during the forecast period of 2018 to 2023. The weakening and bulging of the aorta is called aortic aneurysm. The bulging can cause a leak that spills blood into the body. It can direct the blood flow away from the organs and tissues, causing severe complications, such as kidney damage, heart attacks, stroke, and even death. Thus, endovascular repair can be done by placing a stent-graft in an aneurysm through a small hole in the blood vessels in the groin area.
Numerous factors such as reduced recovery times, low-cost hospitalization charges, and technological advancements in repair devices are expected to drive the growth of the market. For instance, in March 2017, Terumo Corporation completed the acquisition of Bolton Medical, Inc. with the acquired company being a leading innovator in thoracic and abdominal stent graft systems, Terumo Corporation aimed to strengthen its growth in vascular graft segment.
However, stringent government regulation, the preferable alternative of open surgery and various complications such as endoleaks and infections may hamper the market growth during the assessment period.
Key players
  • Cardiatis SA,
  • Cardinal Health,
  • Cook Medical LLC,
  • Endologix, INC.,
  • Jotec GmbH,
  • Medtronic plc,
  • Terumo Corporation,
  • L. Gore & Associates, Inc.,
  • BiFlow Medical Ltd,
  • Boston Scientific Corporation,
  • Braile Biomédica,
  • Endoluminal Sciences Pty Ltd,
  • Endospan Ltd.,
  • Getinge AB,
  • Lemaitre Vascular Inc.
Segmentation
The global endovascular aneurysm repair devices market has been segmented into indication, site, anatomy, and products.
The market, on the basis of indication, has been segmented into the abdominal aortic aneurysm, thoracic aortic aneurysm and others.
The market, based on thoracic aortic aneurysm, has been further segmented into ascending aortic aneurysm, descending aortic aneurysm, thoracoabdominal aortic aneurysm, and thoracic arch aortic aneurysm.
The market, on the basis of the site, has been segmented into infrarenal and pararenal.
The market, based on pararenal site, has been sub-segmented into juxtarenal and suprarenal.
The market, on the basis of anatomy, has been segmented into traditional and complex.
The market, on the basis of products, has been segmented into percutaneous EVAR, fenestrated EVAR, aortic stents and TAA grafts, and others.
Regional Market Summary
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The endovascular aneurysm repair devices market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The Americas is expected to dominate the global endovascular aneurysm repair devices market owing to increasing geriatric population, and well-developed healthcare sector. With the increase in the geriatric population, the prevalence of aneurysms is also expected to rise. The Centers for Disease Control and Prevention (CDC) ranks abdominal aortic aneurysm as one of the top 15 causes of mortality in the United States, but only for those between 85 and 89 years. According to the Centers for Disease Control and Prevention, aortic aneurysms were the primary cause of 9,863 deaths in 2014 in the US.
Europe is expected to hold the second largest position in the global endovascular aneurysm repair devices market. The market growth in this region is attributed to the growing prevalence of aneurysms, availability of funds for research, and favorable reimbursement scenario.
On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to the growing government initiatives for the healthcare sector.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population and continuously developing economies.
Browse Complete 100 Pages Premium Research Report Enabled with 110 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/endovascular-aneurysm-repair-devices-market-6485

       
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Wednesday, 24 April 2019

Ebstein’s Anomaly Market to Observe Significant Growth by 2019

Ebstein's anomaly is a rare congenital disease that occurs due to improper development of the tricuspid valve in the first eight weeks of fetal growth. This disorder occurs when the tricuspid valve that divides the two chambers of the right side of the heart does not form correctly.
Ebstein's anomaly may be due to many factors, including genetics and the environment. Children born in a family with a history of heart defects may be more likely to have Ebstein's anomaly. The mother's exposure to certain medications, such as lithium, can lead to Ebstein's anomaly in the child.
The global Ebstein’s Anomaly market is driven by the increasing number of congenital heart diseases and growing population; growing market players has increased the scope of Ebstein’s Anomaly market. Technological advancements, owing to which new and advanced products are being launched in the market, is another factor propelling the growth of this market.
However, varied stringency of regulatory procedures across the globe and the presence of complex regulatory procedures may hinder the growth of this market.
The global Ebstein’s Anomaly market is expected to grow at a CAGR of 9.0% during the forecast period.
Key Players                                                                                                         
Some of the key players in fungal eye infection market are Ebstein’s Anomaly market are Abbott Vascular, Boston Scientific Corporation, Cordis Corporation, Edwards Lifesciences, Ge Healthcare, Gore Medical, Medtronic, Inc., Numed, Inc., Siemens Healthcare, St. Jude Medical, and Toshiba Corporation among others.

 Intended Audience
  • Pharmaceutical Manufacturers and Suppliers
  • Medical Research Laboratories
  • Research and Development (R&D) Companies
  • Market Research and Consulting Service Providers
  • Potential Investors
Segments                                                                                                                                            
The global Ebstein’s Anomaly market is segmented on the basis of treatment, diagnosis and end users.
On the basis of the treatment, the market is segmented medications and surgical treatment. Surgical Treatment is further segmented into tricuspid valve repair, tricuspid valve replacement, closure of the atrial septal defect, and maze procedure.
On the basis of diagnosis Ebstein’s Anomaly market is segmented into echocardiogram, electrocardiogram (ECG) chest x-ray, cardiac MRI, Holter monitor, pulse oximetry, exercise stress test, electrophysiology study, and cardiac catheterization.
On the basis of end users, the market is segmented into hospitals & surgical centers, and specialty clinics.
Regional Analysis
North America Ebstein’s Anomaly market is rapidly growing in the American region. On a regional basis, the Americas is segmented into North America and South America. North America is segmented into the U.S. and Canada. Increasing number of congenital disorders and growing  population has increased the scope for the Ebstein’s Anomaly market in North America. According to CDC (Centre for Disease Control), it was estimated that about 1 million U.S. children and about 1.4 million U.S. adults were living with CHDs.  Additionally, CHDs affect nearly 1% of―or about 40,000―births per year in the United States.
Europe is the second largest market and holds a healthy share in the global Ebstein’s Anomaly market. The European market is expected to grow steadily during the forecast period owing to the skilled professionals and availability of advanced and accessible treatment facilities. Additionally, wide research and development activities for the treatment of rare disease and increasing government funding boost the market growth.  
Asia Pacific is expected to be the fastest growing market. Increasing prevalence of chronic diseases such as diabetes is the major driver for the market growth. India is the fastest growing region owing to the increasing population. Rising awareness about the health and availability of new treatment methods drive the market in this region. Rising healthcare expenditure and overall growth of healthcare diagnostic and treatment industry also drives the market.
The Middle East & Africa is expected to show the least growth in the market due to some major factors such as lack of awareness, limited access and availability of treatment facilities. In the Middle East, United Arab Emirates is the largest market share owing to the development of healthcare industry and rising availability of specialty care centers.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Transgenic Animals Market size and Key Trends in terms of volume and value 2019

Market Scenario:
Transgenic animals carry a foreign gene deliberately inserted into its genome.  The insertion of the foreign DNA into the host body is carried out by the application of recombinant DNA technology. The transmission of the foreign gene is facilitated through the germ line so that every cell of the targeted animal contains the same modified genetic material. In 1997, Rosie (first transgenic cow) was produced with the aim of generating human protein-enriched milk. The milk was nutritionally balanced as compared to the natural bovine milk and was suitably exploited to meet the special nutritional requirements of the geriatric population and babies. Insulin, growth hormone, and anti-blood clotting factors are some of the products that can be effectively obtained from the milk of transgenic cows, sheep, or goats. Growing biotechnology sector followed by rising R&D expenses is estimated to be a major driver for the market growth during the forecast period. In 2016, the revenue generated by the emerging biotech industries across the globe was estimated to be around USD 139.4 billion. Moreover, increasing prevalence of cardiovascular diseases, diabetes, and other disorders along with the rising healthcare expenditures and growing awareness for the transgenic animals is boosting the market growth.
According to the World Health Organization in 2017, cardiovascular diseases were the main cause of the deaths across the globe. It was estimated that in 2015, approximately 17.7 million people died from cardiovascular diseases, representing 31% of all the global deaths. Of these deaths, an estimated 7.4 million were due to the coronary heart diseases and 6.7 million were due to stroke. However, stringent FDA policies followed by the high developmental cost and reluctance in the acceptance of transgenic products is estimated to restrain the market growth. The cost of producing a transgenic animal may range from USD 20,000 to USD 300,000.
The market for transgenic animals is estimated to grow at an approximate CAGR of 8.60% from 2017 to 2023.
Segmentation
The global transgenic animals market is segmented on the basis of product, techniques, consumables, application, model organisms, and end-user.
On the basis of the product, the market is categorized into PCR, gene gun, microinjections, electroporator, and others. The PCR segment is sub-segmented into real-time PCR, digital PCR systems, and others. On the basis of the techniques, the market is segmented into retrovirus-mediated gene transfer, embryonic stem cell-mediated gene transfer, DNA microinjection, and others. On the basis of the consumables, the market is segmented into fluorescent probes, culture media, and others. On the basis of the application, the market is segmented into recombinant human proteins, monoclonal antibodies, xenotransplantation, and others. On the basis of the model organisms, the market is segmented into mice, rabbit, cows, and others. On the basis of the end-user, the market is segmented into biotechnology industries, research organizations, academic institutes, and others.
Key players for transgenic animals market
Cyagen Biosciences, Charles River, Creative-Biolabs, TRANS GENIC INC.., Ltd., Sutter Instrument Company, Bio-Rad Laboratories, Inc., Spinco Biotech Pvt Ltd., Abbott, Thermo Fisher Scientific Inc., Sigma-Aldrich Co., Accumold, and others are some of the major players for transgenic animals market.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Anaplasmosis Treatment Market in depth study and analysis published, 2019

Anaplasmosis is a bacterial infection that spreads from animals to humans. More rarely, the bacteria that cause anaplasmosis can spread through direct contact with infected animals. The infection can be treated successfully with antibiotics. According to the Centers for Disease Control and Prevention (CDC), the global burden of human anaplasmosis treatment remains high as the organism causes more than 10,000 infections per year worldwide. Usually, anaplasmosis is more common in males than in females and are generally not occurring in infants.
The frequency of reported cases of anaplasmosis is highest among people over 40 years of age. A compromised immune system such as patients undergoing cancer treatments, advanced human immunodeficiency virus infection, prior organ transplants may increase the risk of the severe outcome. Individuals working or spending time in known tick habitats such as the zoo, animal rearing, and farms may be at increased risk for infection.
Although anaplasmosis infections can occur during any time of the year, the majority of cases reported to the CDC have an illness onset during the summer months and peaks in the months of June and July. This period is the season for the proliferation of nymphal black-legged ticks that bite humans and may transmit the pathogen.
The global market for anaplasmosis treatment is expected to grow at a CAGR of approximately 6.3% during the forecast period 2017-2023.
Segmentation
The anaplasmosis treatment market is segmented on the basis of species, diagnosis, application, treatment, and end-users.
On the basis of the species, the market is segmented into Deer tick (Ixodes scapularis), western black-legged tick (Ixodes pacificus), Anaplasmosis phagocytophilum or A. platys
On the basis of the diagnosis, the market is segmented into enzyme-linked immunosorbent assay (ELISA), indirect fluorescent antibody (IFA), and polymerase chain reaction (PCR) tests
On the basis of the application, the market is segmented into humans, pets, livestock, wildlife, and others 
On the basis of the treatment, the market is segmented into antibiotics, vaccines, and others. The antibiotics can be further classified as doxycycline, tetracyclines, chlortetracycline, oxytetracycline, rolitetracycline, minocycline, and others.
On the basis of the end-user, the market is segmented into hospitals & diagnostic centers, academic institutes, pharmaceutical & biotechnology companies, and others.
Key Players
Some of key the players in the global anaplasmosis treatment market are Wyeth Pharmaceuticals (U.S.), Merck Sharp & Dohme (France), Boehringer Ingelheim (France), Bristol-Myers Squibb and Company (U.S.), Glaxosmithkline Inc. (U.S.) Aventis Pharma (Canada), Mylan Pharmaceuticals (U.S.), Pfizer Inc. (U.S.), Teva Pharmaceuticals (Israel), Shire (U.S.), Procter & Gamble, (U.S.), Duramed Pharmaceuticals (U.S.), Takeda Pharmaceuticals (Japan), Ciba Vision (Germany)  Novopharm (Canada), and others.
Regional Analysis
The global anaplasmosis treatment market consists of countries namely America, Europe, Asia Pacific, and the Middle East, and Africa.
The American anaplasmosis treatment is the largest market across the globe owing to the high investment in various private and government-funded research, and increased spending on pharmaceutical industry. This condition is commonly reported from the upper midwestern and northeastern United States. the black-legged tick (Ixodes scapularis) is responsible for transmission of A. phagocytophilum in the upper Midwest and northeastern U.S. These tick species also transmit the agents of Lyme disease (Borrelia burgdorferi) and babesiosis (Babesia species). Moreover, the human co-infections with these organisms have occasionally been reported. Anaplasmosis treatment is now being controlled in North America due to numerous veterinary control measures such as routine screening and vaccination of domestic livestock.
European market is projected to hold the second largest share of the global anaplasmosis treatment market as due to the eradication of these disease from Europe. Although some clinical cases of human granulocytic anaplasmosis have been reported in Europe, mostly from Slovenia, Sweden, and Poland, most cases have occurred in the United States. According to the U.S. National Library of Medicine, the prevalence of Ixodes ricinus ticks in Europe is 3% which is as higher than the United States. The average prevalence rate of A. phagocytophilum infection among humans in Europe was 6.2% in 2010 and is estimated to reach up to 21% by 2020.
The Asia Pacific and the Middle Eastern region are expected to grow at a faster rate due to the factors such as the extensive development of health care infrastructure and growing emphasis on research and development in the healthcare sector.
Browse Complete 110 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/anaplasmosis-treatment-market-5351


About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Refsum Disease Market to Observe Strong Development by 2019

Refsum disease is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene that metabolizes phytanic acid. According to the U.S. National Library of Medicine, more than 90 % cases of refsum disease result from the mutations in PHYH gene, and the remaining cases are caused by mutations in a gene PEX7 gene.
Notably, increasing awareness among people is the key factor driving the refsum disease market. According to the National Organization of Rare Diseases, the age of onset of refsum disorder varies greatly. The disease can occur at any time from early childhood to nearly 50 years of age, but in most cases will have appeared by age 20. Males and females are equally affected in numbers.
Various other push factors such as increasing awareness among people, increasing government assistance, improving regulatory framework, and rising funding and reimbursement continuously contributing to the growth of the global refsum disease market.
Despite these drivers, there are some issues associated with refsum disease market. Some of the challenges in research and development, and poor healthcare system in low and middle-income countries may hinder the growth of the market to some extent.
It is estimated that the refsum disease market is expected to grow at a CAGR 5.4% during the forecast period of 2017-2023.
Intended Audience
  • Pharmaceutical Companies
  • Hospitals & Clinics
  • Research and Development (R&D) Companies
  • Diagnostic Laboratories
  • Government Research Institute
  • Academic Institutes and Universities
Key Players
Some of key the players in the global refsum disease market are Fresenius Kabi, B. Braun Medical Inc., Medline Industries, Inc., Illumina, Inc., Igenomix, Ceuta Healthcare Limited, Cochlear Ltd., Cook, Sonova, William Demant Holding A/S, Nurotron Biotechnology Co. Ltd., Agilent Technologies, Bio-Rad Laboratories, Inc., Sequenom, and others.
Segmentation
The global refsum disease market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of the type, the market is segmented into adult refsum disease, and others. The adult refsum disease is further segmented into adult refsum disease 1, and adult refsum disease 2.
On the basis of the diagnosis, the market is classified into physical examination, molecular genetic testing, prenatal screening tests, preimplantation genetic diagnosis, enzyme analysis, anosmia testing, and others. The molecular genetic testing is further segmented into genotyping, sequencing of gene, amplification or hybridization method, methylation-specific techniques, and others. The prenatal screening tests are further segmented into ultrasound, blood tests, chorionic villus sampling (CVS), amniocentesis, and others.
On the basis of the treatment, the market is classified as medical care, and surgical care. The medical care is further segmented into diet, plasmapheresis, and medication. The sub-segments of medication include keratolytics, and others.
On the basis of the end-user, the market is segmented into hospital, clinics, diagnostic centers, research & academic institutes, and others.
Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/refsum-disease-market-5176
Regional Analysis
The Americas dominate the refsum disease market owing to the rising awareness among people and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.
Europe holds the second position in the refsum disease market. It is expected that the support provided by the government bodies for research & development and improvement in reimbursement policies in healthcare is likely to drive the market of the European region.
The Asia Pacific is the fastest growing refsum disease market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015.
The Middle East & Africa holds the lowest market due to lack of technical knowledge and poor medical facilities.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Tuesday, 23 April 2019

Optical Imaging Market 2019 Global– Key Players, Size, Trends, Growth- Analysis To 2023

Optical imaging is a non-invasive technique in which light is used to interrogate cellular and molecular function in the living body by exploiting the special properties of photons. This market is mainly driven by rising demand for non-invasive procedures, harmful effects of radiation-based imaging, increase in research and development activities in the life sciences sector, and increasing application of optical imaging techniques in drug discovery processes and preclinical research, Moreover factors such as rising geriatric population which leads to increase in cardiovascular, neurological and ophthalmic disorders is also fueling the growth of this market.
The global optical imaging market is expected to be of value USD 1.92 Billion in 2023 and to grow at a depict 10% CAGR during the forecast period.
However, factors such as stringent regulatory approval procedures high costs of instruments, scarcity of skilled operators, and insufficient reimbursements policies for optical imaging procedures restrict market growth.
Segmentation
The global optical imaging market is segmented on the basis of products, techniques, therapeutic area, application, and end-user. Considering the type of product, the market is segmented into imaging systems, software, lenses, illumination systems, cameras and others. Imaging systems are further segmented into optical imaging systems and spectral imaging systems. On the basis of technique, the market is segmented into Optical Coherence Tomography (OCT), photoacoustic imaging, diffused optical tomography, hyperspectral imaging, near-infrared spectroscopy, and super-resolution microscopy.
On a therapeutic area basis, it is segmented into neurology, oncology, ophthalmology, dentistry, cardiology, dermatology, and others. On account of application, the market is segmented into pre-clinical and clinical research, pathological imaging and intraoperative imaging. According to the end-user, the market is segmented into diagnostic imaging centers, hospitals and clinics, research laboratories, and pharmaceutical &biotechnology companies. Based on region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. Americas region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.
Key players
  • Jude Medical, Inc.
  • Carl Zeiss Meditec AG
  • Bioptigen, Inc.
  • Canon Inc
  • Heidelberg Engineering, Inc.
  • Topcon Corporation
  • Perkinelmer, Inc.
  • Koninklijke Philips N.V.
  • Agfa-Gevaert N.V.
Regional Market Summary
In terms of geography, Americas dominates the market for optical imaging owing to increasing prevalence of cardiovascular, neurological and ophthalmic disorders about rising geriatric population which is a major trigger factor for this disease. Additionally, factors such as increasing government initiatives and funding for research in medical devices sector, rising demand for accurate diagnosis, awareness about adverse effects of radiation imaging, ability to provide in-depth images of soft tissues and vascular systems and presence of pharmaceutical giants key players also propel the market growth in this region. For instance, according to National cancer institute, in 2016, around 1,685,210 new cases of cancer were diagnosed in the U.S. Thus, this huge patient pool is going to boost up the market growth during the forecast period.
Europe is the second largest market and holds a healthy share in the global optical imaging market due to major driving factors like availability of advanced treatment facilities, increasing healthcare expenditure, good healthcare infrastructure and flourishing medical device industry due to the presence of major market players. Additionally, knowledge about the benefits of optical imaging over radiation imaging and capability of inhabitants to afford the diagnostics is spurring the market growth.
Asia Pacific is expected to be the fastest growing market with most promising growth possibilities. According to a report published by the department of neurology in 2014, it is estimated that for the current population of 1.27 billion, approximately 30 million people suffer from neurological disorders in India. Thus, owing to the huge patient pool, a faster adaptation of healthcare technology, government initiatives to increase the healthcare quality, availability favorable insurance policies market growth will be accelerated during the forecast period.  Moreover, due to lower cost of clinical trials and research key players have been setting up their regional headquarters and manufacturing plants in Singapore, China, Japan, Korea, and Australia which make a positive growth curve in optical imaging market in future.
Browse Complete 100 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/optical-imaging-market-6172

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Subscribe to: Posts (Atom)